Tirbanibulin 1 % ointment: A narrative review of new data presented at the 11th World Congress of Melanoma in conjunction with 21st European Association of Dermato-Oncology Congress 2025

Ardigò M, Heppt MV, Aguado L, Borgia F, Broganelli P, Coronel Pérez IM, Dirschka TP, Gilaberte Y, Gualdi G, Hobelsberger S, Luque Varela P, Moyano B, Patel GK, Puig S, Savoia P, Zalaudek I (2026)

Publication Type: Journal article, Review article

Publication year: 2026

Journal

Book Volume: 4

Article Number: 100781

DOI: 10.1016/j.ejcskn.2026.100781

Abstract

Purpose: This article provides an overview of the scientific content on tirbanibulin 1 % ointment, summarizing key Phase IV results and real-life experiences with tirbanibulin shared by dermatologists across Europe. Materials and Methods: Summary of posters, oral presentation and symposium discussions related to tirbanibulin presented at the 11th World Congress of Melanoma in conjunction with 21st European Association of Dermato Oncology (EADO) Congress held between 3rd and 5th of April 2025 in Athens, Greece. Results: We report presented data on the efficacy/effectiveness, safety and tolerability of tirbanibulin 1 % ointment for the treatment of actinic keratosis (AK) on the face, scalp and décolleté. We also collected evidence supporting its use in AK in organ transplant recipients (OTR), solar damaged skin, pigmented AK (PAK), proliferative AK, hypertrophic AK, actinic cheilitis (AC), keratinocyte carcinoma (KC) and lentigo maligna (LM). Conclusions: Overall, data from a Phase IV trial and real-world clinical practice suggest that tirbanibulin is an effective, safe and well-tolerated treatment for AK. Tirbanibulin may also be an option for OTR, patients with PAK, proliferative or hypertrophic AK, and even for conditions such as AC or KC, although the sample size is small in some of these groups and further evidence is needed.

Involved external institutions

University of Eastern Piedmont / Università degli Studi del Piemonte Orientale "Amedeo Avogadro" Italy (IT) Humanitas University Italy (IT) Clínica Universidad de Navarra Spain (ES) University of Messina / Università degli Studi di Messina Italy (IT) Hospital Clínic de Barcelona Spain (ES) Centroderm GmbH Germany (DE) Hospital Universitario Miguel Servet Spain (ES) Università degli Studi Gabriele D'Annunzio Italy (IT) Universitätsklinikum Carl Gustav Carus Dresden Germany (DE) Università degli Studi di Trieste Italy (IT) Clínica Dra Páez Spain (ES) Hospital Regional de Málaga Spain (ES) Cardiff University United Kingdom (GB) L'Ospedale Mauriziano di Torino Italy (IT) Hospital Universitario Virgen de Valme Spain (ES)

How to cite

APA:

Ardigò, M., Heppt, M.V., Aguado, L., Borgia, F., Broganelli, P., Coronel Pérez, I.M.,... Zalaudek, I. (2026). Tirbanibulin 1 % ointment: A narrative review of new data presented at the 11th World Congress of Melanoma in conjunction with 21st European Association of Dermato-Oncology Congress 2025. EJC Skin Cancer, 4. https://doi.org/10.1016/j.ejcskn.2026.100781

MLA:

Ardigò, Marco, et al. "Tirbanibulin 1 % ointment: A narrative review of new data presented at the 11th World Congress of Melanoma in conjunction with 21st European Association of Dermato-Oncology Congress 2025." EJC Skin Cancer 4 (2026).

BibTeX: Download